| Lipids Management |
1 |
1 |
| Statins |
0 |
0.95 |
| Muscle |
0 |
0.38 |
| Myalgia |
0 |
0.34 |
| Cardiovascular Risk Management |
0 |
0.8 |
| Hypertension |
0 |
0.24 |
| Liver |
0 |
0.24 |
| Cardiometabolic Risk Factors |
0 |
0.85 |
| Pain Management |
0 |
0.19 |
| Renal Failure |
0 |
0.15 |
| Cardiovascular disease |
0 |
0.85 |
| Orbit |
0 |
0.14 |
| Preventive Medicine |
0 |
0.14 |
| Patient Safety |
0 |
0.11 |
| Adverse Effects |
0 |
0.1 |
| Generics |
0 |
0.1 |
| Myocardial Infarction (MI) |
0 |
0.8 |
| Pain |
0 |
0.1 |
| Texas |
0 |
0.1 |
| Cerebrovascular Accident |
0 |
0.07 |
| Heart |
0 |
0.75 |
| Infarction |
0 |
0.75 |
| Meta-Analysis |
0 |
0.07 |
| Clinical Guidelines |
0 |
0.06 |
| Cataract |
0 |
0.04 |
| Adherence |
0 |
0.03 |
| Atherosclerosis |
0 |
0.75 |
| Dyslipidemia |
0 |
0.7 |
| Fellowship |
0 |
0.03 |
| Geriatrics |
0 |
0.03 |
| Hyperlipidemia |
0 |
0.7 |
| Internet |
0 |
0.03 |
| Myopathy |
0 |
0.03 |
| Pandemic |
0 |
0.03 |
| Patient History |
0 |
0.03 |
| Scholarship |
0 |
0.03 |